Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL6 corepressor (BCOR)
- Target
- BCOR
- Molecular classification
- Transcriptional corepressor, Chromatin regulator, Protein–protein interaction partner
01
Overview
BCL6 corepressor (BCOR) is a ubiquitously expressed protein that acts as a transcriptional corepressor by interacting directly and selectively with the POZ domain of the BCL6 transcription factor[1][2]. BCOR regulates gene expression by recruiting histone deacetylases, thereby modifying chromatin to suppress target genes. It is essential for embryogenesis, including development of eyes, heart, teeth, and other organs, and appears to participate in apoptotic regulation[1][3][4]. Pathogenic mutations in the BCOR gene cause a spectrum of severe congenital syndromes, particularly affecting females, and are also implicated in hematologic malignancies such as acute myeloid leukemia[2][3][4]. Interactions of BCOR are highly specific; it binds BCL6 and selected epigenetic regulators (HDACs) but not most other POZ proteins[1].
- Other names
- BCL6 corepressorBCOR
02
Mechanism of action
Not applicable—BCOR is not currently a therapeutic target for approved drugs.
03
Biological functions
Transcriptional repression (via recruitment to BCL6)Regulation of histone deacetylation (through interaction with class I and II histone deacetylases)Regulation of developmental gene expressionApoptosis regulation
04
Disease associations
Developmental disorders (e.g., oculofaciocardiodental syndrome, microphthalmia syndromes)Cancer (mutation and aberrant expression associated with acute myeloid leukemia, BCL6-driven lymphomas)Other congenital malformations (e.g., cardiac and skeletal defects)
05
Safety considerations
Not applicable for direct targeting (as no drugs are known to interact), though loss-of-function mutations are associated with severe developmental diseases and may be lethal in males
06
Biomarkers
Mutations or deletions in BCOR can serve as genetic biomarkers for certain developmental syndromes (e.g., OFCD, MCOPS2) and for subtype identification in myeloid malignanciesAberrant BCOR expression may be considered a biomarker in some lymphomas
Beyond the preview
Go deeper on BCL6 corepressor (BCOR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL6 corepressor (BCOR).